Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based clinical development solutions, today announced that it will release its second quarter 2012 financial results before the open of the market on Tuesday, July 31, 2012. Tarek Sherif, chief executive officer, and Cory Douglas, chief financial officer, will also hold a conference call at 8:00 a.m. ET for investors and analysts to review these results and discuss the outlook for the third quarter and full year 2012. To participate by telephone, domestic participants may dial 1-877-303-2528 and international participants may dial 1-847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the “Investor” section of Medidata’s website, http://investor.mdsol.com. A replay of the conference call can be accessed through Tuesday, August 14, 2012, by dialing 1-800-585-8367 domestically or 1-404-537-3406 internationally, with the passcode 97331788. An archive of the call will also be hosted on the “Investor” section of Medidata’s website, http://investor.mdsol.com, for a limited period of time. About Medidata Solutions Worldwide Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.